Overview

An Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma

Status:
Recruiting

Trial end date:
2025-04-29

Target enrollment:

Participant gender:

Summary

This first time in human (FTIH) open-label, dose escalation study will assess the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of GSK3326595 in participants with advanced or recurrent solid tumors, as well as clinical activity in participants with a subset of solid tumors and non-Hodgkin's lymphoma (NHL).

Phase:

Phase 1

Details

Lead Sponsor:

GlaxoSmithKline

Treatments:

GSK-3326595
Pembrolizumab